Mergers & Acquisitions - Financial, Pharmaceutical

Filter

Current filters:

FinancialPharmaceutical

Popular Filters

1 to 25 of 80 results

Reckitt Benckiser outlines plans for demerger of the RB Pharma business

17-11-2014

Following the announcement made by UK-based consumer goods giant Reckitt Benckiser that it was pursuing…

FinancialIndiviorMergers & AcquisitionsPharmaceuticalReckitt BenckiserReckitt Benckiser Pharmaceuticals

Fresenius Kabi dumps planned Russian joint venture

09-11-2014

Fresenius Kabi and its partners Sistema JSFC and Zenitco Finance Management have mutually agreed to terminate…

BinnopharmFinancialFreseniusFresenius KabiMergers & AcquisitionsPharmaceuticalProductionRussia

CSL buys Novartis’ influenza vaccines business for $275 million

CSL buys Novartis’ influenza vaccines business for $275 million

27-10-2014

Swiss pharma major Novartis has agreed to divest its influenza vaccines business to Australia’s CSL…

Anti-viralsbioCSLCSL LimitedFinancialMergers & AcquisitionsNovartisPharmaceuticalVaccines

Shire to receive $1.635 billion break fee from AbbVie

Shire to receive $1.635 billion break fee from AbbVie

21-10-2014

The board of Ireland-headquartered drugmaker Shire has said there is now no realistic prospect of AbbVie…

AbbVieBusiness FinanceCity Code on Takeovers and MergersFinancialMergers & AcquisitionsMergers and acquisitionsPharmaceuticalShireUSA

AbbVie reconsidering $54.6 billion acquisition of Shire

AbbVie reconsidering $54.6 billion acquisition of Shire

15-10-2014

US drugmaker AbbVie has told Ireland-headquartered Shire of its board of directors' intention to meet…

AbbVieFinancialIrelandMergers & AcquisitionsPharmaceuticalShire

Avalon Ventures and GlaxoSmithKline launch two new companies

23-09-2014

Avalon Ventures today announced the launch of two new companies formed through its collaboration with…

Avalon VenturesFinancialGlaxoSmithKlineHematologyMergers & AcquisitionsPharmaceuticalRare diseasesSilarus TherapeuticsThyritope Biosciences

US Treasury to crack down on tax inversion M&A deals

US Treasury to crack down on tax inversion M&A deals

23-09-2014

The USA’s Department of the Treasury announced on Monday that it is taking action to reduce the tax…

FinancialMergers & AcquisitionsPharmaceuticalPoliticsUSA

Mood lifts for Medtech in first half of 2014, while Pharma sector faces new struggles

Mood lifts for Medtech in first half of 2014, while Pharma sector faces new struggles

20-08-2014

An M&A frenzy that accounted for nearly $90 billion of equity set the pace for the first half of 2014…

FinancialGlobalJonathan GardnerMergers & AcquisitionsPharmaceutical

Allergan attacks Valeant’s financial results

Allergan attacks Valeant’s financial results

06-08-2014

US Botox maker Allergan, the subject of a hostile $53 billion takeover attempt by Canada’s Valeant…

AllerganBusiness FinanceCanadaFinancialMergers & AcquisitionsPharmaceuticalUSAValeant PharmaceuticalsValeant Pharmaceuticals International

Reckitt Benckiser to spin out pharma; GSK views Consumer options

Reckitt Benckiser to spin out pharma; GSK views Consumer options

28-07-2014

UK-based consumer goods giant Reckitt Benckiser plans to spin off its USA-based pharmaceutical business,…

FinancialGlaxoSmithKlineMergers & AcquisitionsNeurologicalPharmaceuticalReckitt BenckiserSuboxoneUK

Shire succumbs to AbbVie’s yet again increased offer of £53.20 per share

Shire succumbs to AbbVie’s yet again increased offer of £53.20 per share

14-07-2014

Ireland-headquartered Shire, which just on Friday confirmed it had finally entered talks with suitor…

AbbVieAdalimumabFinancialIrelandMergers & AcquisitionsPharmaceuticalShireUSA

Pharma more optimistic about future despite upcoming industry consolidation

Pharma more optimistic about future despite upcoming industry consolidation

13-06-2014

More than 69% of senior players within the pan-world pharma industry expect to see a year-on-year increase…

FinancialGlobalMergers & AcquisitionsPharmaceutical

Takeover target Allergen reports strong 1st-qtr sales growth

07-05-2014

US drugmaker Allergan reported a strong set of first-quarter 2014 financial results, with global sales…

AllerganFinancialMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023

06-05-2014

In a bid to explain its rejection of US pharma giant Pfizer’s increased takeover bid for the Anglo-Swedish…

AstraZenecaFinancialMergers & AcquisitionsPfizerPharmaceuticalResearch

Pfizer’s 4th-qtr 2014 profits and sales slump on generic competition

Pfizer’s 4th-qtr 2014 profits and sales slump on generic competition

06-05-2014

US pharma giant Pfizer, which is aggressively pursuing a takeover of Anglo-Swedish drug major AstraZeneca,…

AstraZenecaFinancialMergers & AcquisitionsPfizerPharmaceutical

Fresenius Kabi signs joint venture with Russia’s Binnopharm

Fresenius Kabi signs joint venture with Russia’s Binnopharm

28-04-2014

Germany-based health care group Fresenius Kabi is entering into a joint venture with Russia’s Sistema…

BinnopharmBusiness FinanceBusiness FinanceFinancialFreseniusFresenius KabiGermanyHealth careHealthcareMergers & AcquisitionsPharmaceuticalRussiaUSD

Allergan adopts stockholder rights plan

23-04-2014

USA-based Allergan, the subject of a hostile takeover bid from Canada’s Valeant Pharmaceuticals reported…

AllerganFinancialMergers & AcquisitionsPharmaceuticalValeant Pharmaceuticals

Vectura to buy Germany’s Activaero for 130 million euros

Vectura to buy Germany’s Activaero for 130 million euros

14-03-2014

UK developer of inhaled therapies Vectura says it is acquiring privately-held German company Activaero…

ActivaeroFinancialMergers & AcquisitionsPharmaceuticalRespiratory and PulmonaryVectura

Fitch affirms Actavis at “BBB-” on Forest Labs acquisition; outlook Stable

20-02-2014

Fitch Ratings has affirmed the ratings of generic drugs major Actavis and subsidiaries at “BBB-”…

ActavisFinancialForest LaboratoriesMergers & AcquisitionsPharmaceutical

Increasing investment in Latin American pharma market

Increasing investment in Latin American pharma market

12-02-2014

Around $12.7 billion has been invested in Latin America’s pharmaceutical market through mergers and…

ArgentinaBrazilChileEcuadorFinancialMergers & AcquisitionsPharmaceuticalSouth America

Medigene’s buy of Trianta is “lucrative move” say analysts

31-01-2014

Medigene’s 4 million euro ($5.5 million) purchase of fellow German company Trianta Immunotherapies…

FinancialImmunologicalsMedigeneMergers & AcquisitionsOncologyPharmaceuticalTrianta ImmunotherapiesUSA

Bayer takes advantage of low interest rates, issuing 2 billion euros of bonds

Bayer takes advantage of low interest rates, issuing 2 billion euros of bonds

22-01-2014

German pharma and life sciences group Bayer says it is taking advantage of currently low interest rates…

AlgetaBayerFinancialMergers & AcquisitionsPharmaceutical

NeXeption forms new company, Alexar Therapeutics, to develop novel LXR agonist portfolio

03-01-2014

US biopharma management company NeXeption says it has secured $21.5 million in Series A financing to…

A-110Alexar TherapeuticsDermatologicalsFinancialMergers & AcquisitionsNeXeptionPharmaceuticalResearch

1 to 25 of 80 results

Back to top